1461095179-94164a01-2242-406b-8870-a767c332dde8

1. A compound of Formula I:
wherein
R1 is selected from the group consisting of halogen, C1-6 haloalkyl and C1-6 haloalkoxy;
R2 is selected from the group consisting of \u2014CN, C1-6 haloalkyl, C1-6 haloalkoxy, \u2014C(O)OR2a and \u2014C(O)NR2aR2b;
R2a and R2b are each independently selected from the group consisting of H, C1-6 alkyl and C3-8 cycloalkyl, or are taken together to form a 5- or 6-membered heterocycloalkyl ring;
X is \u2014N\u2014:
subscript m is an integer from 1 to 3;
and salts and isomers thereof.
2. The compound of claim 1, wherein
R1 is selected from the group consisting of halogen, C1-6 haloalkyl and C1-6 haloalkoxy;
R2 is selected from the group consisting of C1-6 haloalkyl, C1-6 haloalkoxy, \u2014C(O)OR2a and \u2014C(O)NR2aR2b;
R2a and R2b are each independently selected from the group consisting of H, C1-6 alkyl and C3-8 cycloalkyl;
X is \u2014N\u2014;
subscript m is an integer from 1 to 3;
and salts and isomers thereof.
3. The compound of claim 1, wherein R2 is selected from the group consisting of \u2014C(O)OR2a and \u2014C(O)NR2aR2b.
4. The compound of claim 1, having the formula:
5. The compound of claim 1, having the formula:
6. The compound of claim 1, having the formula:
7. The compound of claim 1, having the formula:
wherein R1a and R1b are each independently selected from the group consisting of halogen and C1-6 haloalkyl.
8. The compound of claim 1, having the formula:
9. The compound of claim 1, selected from the group consisting of:
10. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
11. The compound of claim 1, having the formula:
12. A compound of Formula I:
wherein
R1 is selected from the group consisting of halogen, C1-6 haloalkyl and C1-6 haloalkoxy;
R2 is \u2014C(O)NR2aR2b;
R2a and R2b are each independently selected from the group consisting of H, C1-6 alkyl and C3-8 cycloalkyl, or are taken together to form a 5- or 6-membered heterocycloalkyl ring;
X is selected from the group consisting of \u2014CH\u2014 and \u2014N\u2014;
subscript m is an integer from 1 to 3;
and salts and isomers thereof.
13. The compound of claim 12, having the formula:
14. The compound of claim 12, having the formula:
wherein R1a and R1b are each independently selected from the group consisting of halogen and C1-6haloalkyl.
15. The compound of claim 12, having the formula:
16. The compound of claim 12, selected from the group consisting of:
17. The compound of claim 12, having the formula:
18. A pharmaceutical composition comprising a compound of claim 12 and a pharmaceutically acceptable excipient.
19. A compound having the formula:
wherein
wherein R1a and R1b are each independently selected from the group consisting of halogen and C1-6 haloalkyl;
R2 is selected from the group consisting of \u2014CN, C1-6 haloalkyl, C1-6 haloalkoxy, \u2014C(O)OR2a and \u2014C(O)NR2aR2b;
R2a and R2b are each independently selected from the group consisting of H, C1-6 alkyl and C3-8 cycloalkyl, or are taken together to form a 5- or 6-membered heterocycloalkyl ring;
X is selected from the group consisting of \u2014CH\u2014 and \u2014N\u2014;
and salts and isomers thereof.
20. The compound of claim 19, wherein R2 is selected from the group consisting of \u2014C(O)OR2a and \u2014C(O)NR2aR2b.
21. The compound of claim 19, having the formula:
22. The compound of claim 19, selected from the group consisting of:
23. The compound of claim 19, having the formula:
24. A pharmaceutical composition comprising a compound of claim 19 and a pharmaceutically acceptable excipient.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for preventing or ameliorating neural damage in a mammalian fetus or newborn offspring due to maternal gestational hypertension comprising:
administering to a pregnant female an effective amount of germination activated sporoderm-broken Ganoderma lucidum spores (GLSs); wherein said pregnant female has gestational hypertension.
2. The method according to claim 1, wherein said pregnant female is a human.
3. The method according to claim 1, wherein said pregnant female is a rodent.
4. The method according to claim 1, wherein said gestational hypertension is preeclampsia.
5. The method according to claim 1, wherein said preeclampsia is caused by N-omega-nitro-L-arginine methyl ester.
6. The method according to claim 1, wherein said neural damage is a decrease in cell proliferation.
7. The method according to claim 1, wherein said neuronal damage is a decrease in neuron number.
8. The method according to claim 1, wherein said effective amount of GLSs is administered orally.
9. The method according to claim 1, wherein said neural damage is in a hippocampus region of a brain.
10. The method according to claim 1, wherein said GLSs are prepared by soaking Ganoderma spores in a solution which is selected from the group consisting of water, saline, and a nutritional solution to cause the spores to germinate; placing said germination-treated Ganoderma spores in a culture box at a relative humidity of 65-98% and temperature of 18-48\xb0 C. to cause the germinated Ganoderma spores to activate; and breaking sporoderm of said germination activated Ganoderma spores to produce said GLSs.
11. The method according to claim 1, wherein said effective amount of GLSs is between 0.01 and 20 gkg body weightday.
12. The method of claim 11, wherein said effective amount is between 0.1 and 20 gkg body weightday.
13. A method for preventing or ameliorating increase expression of hippocampal hypoxia inducible factor (HIF-1a) in a mammalian embryo due to maternal gestational hypertension comprising:
administering to a pregnant female an effective amount of germination activated sporoderm-broken Ganoderma lucidum spores (GLSs); wherein said pregnant female has gestational hypertension.
14. The method according to claim 13, wherein said pregnant female is a human.
15. The method according to claim 13, wherein said gestational hypertension is caused by preeclampsia.
16. The method according to claim 15, wherein said preeclampsia is caused by N-omega-nitro-L-arginine methyl ester.
17. A method preventing or ameliorating increase expression of hippocmpal vascular endothelial growth factor (VEGF) in a mammalian embryo due to maternal gestational hypertension comprising:
administering to a pregnant female an effective amount of germination activated sporoderm-broken Ganoderma lucidum spores (GLSs); wherein said pregnant female has gestational hypertension.
18. The method according to claim 17, wherein said pregnant female is a human.
19. The method according to claim 17, wherein said gestational hypertension is caused by preeclampsia.
20. The method according to claim 19, wherein said preeclampsia is caused by N-omega-nitro-L-arginine methyl ester.